Treatments for asthma that modulate eosinophil action are available; Reslizumab and Mepolizumab are anti-IL-5 antibody therapies that may have potential in treatment of viral respiratory disease, if eosinophils are activated [28, 29]. Here, IL5 is linked to asthma.